trending Market Intelligence /marketintelligence/en/news-insights/trending/-wP2yz_gAGPFq6F1Ilh6HA2 content esgSubNav
In This List

Aptose's leukemia drug receives US FDA's orphan drug designation

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Aptose's leukemia drug receives US FDA's orphan drug designation

Aptose Biosciences Inc.'s CG'806 received the U.S. Food and Drug Administration's orphan drug designation to treat acute myeloid leukemia, a type of blood and bone marrow cancer.

CG'806 targets the FLT3 receptor which is one of the most frequently mutated genes in acute myeloid leukemia patients.

The FDA's orphan drug designation supports the development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S.

Orphan drug designation provides Aptose certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.